γ-Seminoproteinの前立腺癌血清マーカーとしての有用性

Abstract

未治療前立腺癌30例, 既治療前立腺癌47例, 前立腺肥大症44例, 前立腺炎12例, および膀胱腫瘍8例の計141例についてγ-SmおよびPAPを測定し比較検討した.前立腺癌未治療例のγ-Sm値は23.2±18.3 ng/mlで, 前立腺癌既治療例では4.7±8.3 ng/ml, 前立腺肥大症例では3.6±3.3, 前立腺炎例では2.0±2.0, および膀胱腫瘍例においては1.8±0.8であった.前立腺癌未治療例は, 前立腺癌既治療例, 前立腺肥大症例, および前立腺炎例と比較して有意に高値であった.γ-Smは各stageおよび各分化度とも前立腺良性疾患例と比べて有意に高値を示し, 臨床病期の進行にしたがって高値を示す傾向を認めたが, 組織分化度においては中分化型が最も高値を認めた.また, 治療経過においてγ-SmはPAPと血中動態が解離する傾向を示した

The serum levels of gamma-Seminoprotein (gamma-Sm) were determined by enzyme immunoassay in 77 patients with prostatic cancer (30 untreated and 47 treated), 44 patients with benign prostatic hypertrophy and 12 patients with prostatitis. Serum levels of gamma-Sm in each disease were as follows; untreated prostatic cancer 23.2 +/- 18.3 ng/ml (positive rate 93%), treated prostatic cancer 4.7 +/- 8.3 (positive rate 25.5%), benign prostatic hypertrophy 3.6 +/- 3.3 (positive rate 23.7%), prostatitis 2.0 +/- 2.0 (positive rate 7.7%). Serum gamma-Sm levels in prostatic cancer were higher in advanced stage but relatively low in poorly differentiated adenocarcinoma. We consider that the level of serum gamma-Sm is a useful tumor marker as well as prostatic acid phosphatase (PAP) in diagnosis and follow-up of the patients with prostatic cancer.